A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 76
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : BDQ
Long Form : bedaquiline
No. Year Title Co-occurring Abbreviation
2020 Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis. MDR-TB, MDRFQ
2020 Improved Synthesis and Isolation of Bedaquiline. dr, SFC
2020 Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis. IA
2020 Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis. DLM, DR, DST, MDR-TB, RNTCP, TB, WHO, XDR
2020 Plasma pharmacokinetics of bedaquiline administered by nasogastric tube in an intensive care unit. NGT, TB
2020 TBAJ-876 Displays Bedaquiline-Like Mycobactericidal Potency without Retaining the Parental Drug's Uncoupler Activity. ---
2020 TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus. ---
2020 The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection. ---
2020 Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives. MDR, Mtb, RIN, TB, XDR
10  2020 Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid. DLM, MDR/XDR, TB, WGS
11  2019 Antituberculosis Drug Interactions with Membranes: A Biophysical Approach Applied to Bedaquiline. anti-TB, Chol, CL, DMPC, DMPG, MLVs, SAXS, TOCL, WAXS
12  2019 Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs. AC, CFZ, DLM, PRS, PZA, TB
13  2019 Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study. DLM, MDR-TB
14  2019 Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis. AE, DLM, DR-TB
15  2019 Effect of bedaquiline on the functions of rat liver mitochondria. ---
16  2019 Halting ionic shuttle to disrupt the synthetic machinery-Structural and molecular insights into the inhibitory roles of Bedaquiline towards Mycobacterium tuberculosis ATP synthase in the treatment of tuberculosis. ATP, Mtb
17  2019 High Prevalence of Bedaquiline Resistance in Treatment-Naive Tuberculosis Patients and Verapamil Effectiveness. ---
18  2019 Identifying Regimens Containing TBI-166, a New Drug Candidate against Mycobacterium tuberculosis In Vitro and In Vivo. anti-TB, LZD, PMD, PZA, RFP
19  2019 In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria. MBC, SGM
20  2019 In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates. DEL, FICIs, MFX, MICs, REMA, RIF, TB, XDR
21  2019 Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India. AE, CAP, DR-TB, NITRD, RNTCP
22  2019 Interaction of the anti-tuberculous drug bedaquiline with artificial membranes and rat erythrocytes. ---
23  2019 Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. IQR
24  2019 Mode-of-action profiling reveals glutamine synthetase as a collateral metabolic vulnerability of M. tuberculosis to bedaquiline. GS, Mtb, TB
25  2019 No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis. CLO, GAT, LZD, MFX, MIC, XDR-TB
26  2019 Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa. FS, INH, LPA
27  2019 Re-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline. ---
28  2019 Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay. CFZ, CLR, ETC, RIF, RPT, STR
29  2019 Successful implementation of bedaquiline for multidrug-resistant TB treatment in remote Papua New Guinea. aDSM, MDR-TB
30  2019 Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: Aretrospective cohort analysis. ---
31  2019 TBAJ-876 Retains Bedaquiline's Activity against Subunits c and epsilon of Mycobacterium tuberculosis F-ATP Synthase. NMR
32  2019 The TetR Family Transcription Factor MAB_2299c Regulates the Expression of Two Distinct MmpS-MmpL Efflux Pumps Involved in Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus. CFZ
33  2019 Validation of bedaquiline drug-susceptibility testing by BACTEC MGIT 960 system for Mycobacterium tuberculosis. DST
34  2018 Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages. LNZ, Mtb, RIF, TB
35  2018 Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis. ACERs, DR-TB, ICER, LCR, SCR
36  2018 Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens. FDA, MDR-TB, MDR-TB, MOTT, Mtb
37  2018 Chitosan nanoparticles as a promising approach for pulmonary delivery of bedaquiline. DPI, NPs
38  2018 Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in children. CFZ, DLM, LVX, LZD, MDR-TB, MFX, PK, PTM
39  2018 Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study. BMD, CFZ, ECVs, MDR-TB, MIC, RAVs
40  2018 Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay. HFIM, LZD, URSA
41  2018 Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis. DLM, MDR-TB
42  2018 Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis. ADRs, DALYs, ICER, SLIs
43  2018 Ionophoric effects of the antitubercular drug bedaquiline. ---
44  2018 Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia. HCV, MDR-TB
45  2018 Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169). CLM, CLO, DMD, MCZ, MDR, STZ, TB, UPPS, XDR
46  2018 Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis. CFZ, CYP3A4, DR-TB, PK
47  2018 Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling. MDR-TB
48  2018 Supramolecular strategy for reducing the cardiotoxicity of bedaquiline without compromising its antimycobacterial efficacy. ---
49  2018 Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis. anti-TB, CFZ
50  2017 Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis. MXF, PMD, PZA, TB
51  2017 Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish. ---
52  2017 Bedaquiline: Fallible Hope Against Drug Resistant Tuberculosis. Mtb, TB
53  2017 Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. CFZ, DLM, MDR-TB, MFX, NTM
54  2017 Dose- and Time-dependency of the Toxicity and Pharmacokinetic Profiles of Bedaquiline and Its N-desmethyl Metabolite in Dogs. MDR-TB, PLD
55  2017 Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease. atpE
56  2017 Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. DLM, MDR-TB, TB
57  2017 In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria. MBC, MIC, NTM
58  2017 In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China. CLO, DMD, GAT, LZD, MFX, XDR-TB
59  2017 Modeling the impact of bedaquiline treatment strategies on the multidrug-resistant tuberculosis burden in India. MDR-TB
60  2017 Operational aspects of bedaquiline implementation in Swaziland: report from the field. MDR-TB
61  2017 Structural Simplification of Bedaquiline: the Discovery of 3-(4-(N,N-Dimethylaminomethyl)phenyl)quinoline-Derived Antitubercular Lead Compounds. MDR
62  2016 Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice. PZA
63  2016 Comparison of Effectiveness Between Delamanid and Bedaquiline Among Patients with Multidrug-Resistant Tuberculosis: A Markov Model Simulation Study. DLM, MDR-TB, QALY
64  2016 Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis. LZD, PMD, PZA, SZD, TB
65  2016 Effect of Chromatographic Conditions on Enantioseparation of Bedaquiline Using Polysaccharide-based Chiral Stationary Phases in RP-HPLC. ---
66  2016 Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis. DDIs, NCA, PK
67  2016 Selected questions and controversies about bedaquiline: a view from the field. TB, XDR-TB
68  2016 The experience of bedaquiline implementation at a decentralised clinic in South Africa. MDR-TB
69  2015 Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. ATP, MDR-TB
70  2015 Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. ART, HIV, XDR-TB
71  2014 A Mycobacterium tuberculosis cytochrome bd oxidase mutant is hypersensitive to bedaquiline. TB
72  2014 Acquired resistance of Mycobacterium tuberculosis to bedaquiline. CFZ
73  2014 Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. ---
74  2014 Towards a new combination therapy for tuberculosis with next generation benzothiazinones. PBTZ, TB
75  2013 Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207). ---
76  2013 Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. EFV, RSE, TB